In this latest episode of After Market, Race Oncology Ltd CEO and Managing Director Daniel Tillett spoke with Proactive's Jonathan Jackson about updating an older, previously approved chemotherapy drug to reduce side effects, particularly cardiac-related risks, while maintaining or enhancing therapeutic efficacy.
Race Oncology's development of a reformulated cancer drug is designed to improve chemotherapy outcomes. The initiative centres on updating an older, previously approved chemotherapy drug to reduce side effects, particularly cardiac-related risks, while maintaining or enhancing therapeutic efficacy.
Tillett noted the longstanding issue of severe side effects associated with chemotherapy and explained how the company’s reformulation, when used alongside anthracyclines, could mitigate these effects. Anthracyclines are a key component of many cancer treatment regimens, and the reformulated drug aims to work in tandem with them to improve safety and outcomes for patients.
The company is currently progressing towards clinical trials, which are expected to yield important data regarding the drug's performance in human subjects. Tillett emphasised the commercial opportunity given the continued reliance on anthracyclines in cancer care.